

Frédéric Collet elected as Chairman of Leem

New strategy, new governance, fresh
impetus:

"Leem is geared up and ready to go! "



On Tuesday, 9 July 2019, the Board of Directors of Leem (French Association of Pharmaceutical Companies) elected Frédéric Collet, President of Novartis France, as its chairman. This election ushers in a major reform of the workings of the professional association following the decision by the Board of Directors to structure its organisation around 6 strategic committees and 3 cross-industry committees of experts.

At its meeting on 9 July, Leem's Board of Directors elected Frédéric Collet, President of Novartis France, as Chairman of the professional association. A Leem Board Member since 2013, Frédéric Collet served as Secretary to its Executive Board from September 2018 to June 2019. In this capacity he has stood as Acting Chair since February 2019 in the absence of Philippe Tcheng due to ill health. He has served as Head of European Laboratories and as Chair of Leem's Cancer Committee.

"The accelerated pace of therapeutic innovation has prompted us to review Leem's position in an environment where patient access to innovative treatments is a major challenge, according to Frédéric Collet. I want our team to engage in this process by leveraging our skills and expertise to achieve recognition for Leem in terms of its service to patients, its social and societal involvement, its modern practices, and its contribution to the discussions on health. "

A new Chair embodying a modern vision of the industry


Frédéric Collet, aged 55, is a graduate of the Institut d'Etudes Politiques de Paris and of University of Paris 2. He began his career in the cosmetics industry (Henkel Group) in France and Great Britain, and in 2005 joined the Novartis group and its ophthalmic medical devices business as CEO of Ciba Vision. In 2009, he took over as President of Sandoz France (generic and biosimilar pharmaceuticals). In 2015, he was appointed Chief Executive Officer of Novartis Oncology for France and was involved the development of this Group's new strategic division. He successfully integrated GSK's activities in haematology, oncology and rare diseases into Novartis.

Frédéric Collet has served as President of Novartis France since April 2017. It is in this capacity that he heads the Group's Executive Committee, which encompasses the activities of Novartis Pharma and Oncology, Sandoz and the Huningue Biotechnology Centre. Additionally, he is Chief Executive Officer of Novartis Oncology in France, Director of AAA (Advanced Accelerator Applications), a Novartis subsidiary, and President of CellforCure.

A simpler governance structure organised around 6 strategy committees

The election of Frédéric Collet has ushered in a major reform of Leem's operational structure that was headed by Leem's new Chair in the first half of 2019 while serving as Secretary of its Executive Board. The aim is to bring greater fluidity to the workings of the decision-making bodies and to better distinguish between the roles and responsibilities of the Board of Directors and those of the Executive Board. Leem's ambition therefore is to adapt to both changes within the industry and the needs of its members by making its work more efficient and transparent and by improving information sharing.

The Board of Directors will be dedicating itself fully to driving the strategic priorities presented by **6 committees**:



For its part, the Executive Board will monitor the work of the **3 cross-industry committees of experts** who will be lending their expertise and contributing to the work of the strategy committees:

Legal & tax affairs and
compliance
President : **Philippe Maugendre**
- Sanofi

Communications
President : **Catherine Rives** -
UCB Pharma

Digital, data and new
technologies
President : **Martin Dubuc** -
Biogen France

Each strategy and expert committee will be led and facilitated by a two-person team comprising a director appointed by Leem's Board of Directors and a Leem director and member of the Executive Committee.

The new "**digital, data and new technologies**" cross-industry committee of experts will be enlisted to advise the sector on the issues and prospects of digital technology, artificial intelligence and e-health.

In another new development, **Leem will designate an SME contact person** to ensure that the specificities of these companies are taken into greater account and incorporated into its discussions and activities.

"This new organisational structure will give fresh impetus to the successful implementation of all Leem's projects. As a result, our team is geared up and ready to deal effectively with the items high on the agenda when we reconvene, namely follow-up of the meeting of the Strategic Council for the Healthcare Industries (CSIS), the Social Security Finance Bill (PLFSS) for 2020, renegotiation of the framework agreement, reform of the assessment process ... A forward-looking Leem fully playing its role as a health partner and focused on its primary task of developing innovative treatments and making them available to patients on socially acceptable terms", concludes Frédéric Collet.

Interview vidéo de Frédéric Collet, Président du Leem : <https://dai.ly/k2KItCOU6o145au45Ut>

Vidéo pédagogique sur la nouvelle gouvernance du Leem : <https://dai.ly/kRFdGw2peBnGvZu4zGc>

[For more information please contact the press room at www.leem.org](http://www.leem.org)

Press contacts:

Stéphanie BOU - tel.: +33 (0)1 45 03 88 38 - e-mail: sbou@leem.org

Virginie PAUTRE – Tel.: +33 (0)1 45 03 88 87 - e-mail: vpautre@leem.org

Julie AGRON – Tel.: +33 (0)1 45 03 86 82 - e-mail: jargon@leem.org